Details of the Drug

General Information of Drug (ID: DMKCIUZ)

Drug Name
Daratumumab
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Approved [1]
Drug Type
Antibody
Sequence
>heavy chain
EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA
RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 4017 mgday/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 592 mg/L [2]
Clearance
The clearance of drug is 171.4 +/- 95.3 mL/day [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 +/- 9 days [3]
Metabolism
The drug is metabolized via proteolytic enzymes [4]
Vd
The volume of distribution (Vd) of drug is 4.7 +/- 1.3 L [3]
Cross-matching ID
DrugBank ID
DB09331
TTD ID
D0RV4P

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclic ADP-ribose hydrolase 1 (CD38) TTPURFN CD38_HUMAN Not Available [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bone marrow
The Studied Disease Multiple myeloma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cyclic ADP-ribose hydrolase 1 (CD38) DTT CD38 8.33E-02 0.22 0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Daratumumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Daratumumab and Siponimod. Multiple sclerosis [8A40] [6]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Daratumumab and Ocrelizumab. Multiple sclerosis [8A40] [7]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Daratumumab and Ozanimod. Multiple sclerosis [8A40] [8]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Daratumumab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7395).
2 FDA Approved Drug Products: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use
3 FDA Approved Drug Products: Darzalex Daratumumab Intravenous Injection
4 Elliott S, Pham E, Macdougall IC: Erythropoietins: a common mechanism of action. Exp Hematol. 2008 Dec;36(12):1573-84. doi: 10.1016/j.exphem.2008.08.003. Epub 2008 Oct 14.
5 Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]